Literature DB >> 16759634

Apolipoprotein A-I-mimetic peptides with antioxidant actions.

Su Duy Nguyen1, Tae-Sook Jeong, Dai-Eun Sok.   

Abstract

To augment antioxidant action of apolipoprotein A-I (Apo A-I)-mimetic peptide, the peptide F3,6,14,18 18A (DWFKAFYDKVAEKFKEAF) was modified by incorporating antioxidant amino acid residues. Introduction of His residue at position 2 or 3 at N-terminal of the peptide remarkably enhanced antioxidant action against Cu2+ oxidation of LDL and the capability of sequestering Cu2+. Likewise, the substitution of Ala for Cys residue at position 12 increased antioxidant action against Cu2+ oxidation of LDL. Additionally, the Cys substitution contributed to enhanced capabilities in the removal of hypochlorous acid (HOCl) and 13-hydroperoxyoctadecadienoic acid. Furthermore, the combined incorporation of His and Cys residues enhanced antioxidant actions in preventing Cu2+ oxidation and reducing HOCl and hydroperoxide levels. Separately, in solubilizing phosphatidylcholine, either peptides with His residue at N-terminal position 2 or 3, or those containing Cys residue at position 11 or 12 were equipotent to peptide F3,6,14,18 18A. Further, the lipid-solubilizing ability of those containing both His and Cys residues was comparable to that of peptide F3,6,14,18 18A. In support of this, a similar structural importance was observed with Trp fluorescence study illustrating the penetration of peptides in phosphatidylcholine liposome. Besides, the modified peptides were also comparable to peptide F3,6,14,18 18A in restoring phosphatidylserine-induced loss of PON1 activity. These results indicate that the insertion of His or Cys residue into peptide F3,6,14,18 18A at appropriate positions could lead to enhanced antioxidant action with no significant change of lipid-solubilizing action.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16759634     DOI: 10.1016/j.abb.2006.04.010

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

1.  Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Authors:  David O Osei-Hwedieh; Marcelo Amar; Dmitri Sviridov; Alan T Remaley
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

2.  D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD.

Authors:  Ekambaram Ganapathy; Feng Su; David Meriwether; Asokan Devarajan; Victor Grijalva; Feng Gao; Arnab Chattopadhyay; G M Anantharamaiah; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Int J Cancer       Date:  2011-05-26       Impact factor: 7.396

3.  HDL and Oxidation.

Authors:  Qi Zhang; Zongzhe Jiang; Yong Xu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 4.  High-density lipoprotein mimetics: promises and challenges.

Authors:  Dmitri Sviridov; Alan T Remaley
Journal:  Biochem J       Date:  2015-12-15       Impact factor: 3.857

Review 5.  HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.

Authors:  Alan T Remaley; Marcelo Amar; Dmitri Sviridov
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-10

Review 6.  Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit.

Authors:  Fernando Brites; Maximiliano Martin; Isabelle Guillas; Anatol Kontush
Journal:  BBA Clin       Date:  2017-08-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.